Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF

  80% confidence

• HARMONi-A represents the first statistically significant overall survival benefit achieved in a Phase III study by an ivonescimab-containing regimen

  80% confidence

• Based on the results of the multiregional HARMONi study, we plan to submit a Biologics License Application (BLA)

  80% confidence

• Summit intends to open clinical trial sites in the United States for the Phase III study in CRC by the end of 2025

  80% confidence

• Over 3,000 patients have been treated with ivonescimab in clinical studies globally, and over 40,000 patients when considering those treated in a commercial setting in China

  80% confidence

• Ivonescimab has a half-life of 6 to 7 days after the first dose increasing to approximately 10 days at steady state dosing

  80% confidence

• In China, over 40,000 patients have been treated with ivonescimab in either a clinical or commercial setting

  80% confidence

• This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials

  80% confidence

Cited in these Via News reports

• Global Precision Oncology Race Intensifies as Biotech Firms Across Three Continents Target Regulatory Milestones →